Drug Profile
Research programme: MAP kinase kinase inhibitors - Oncodesign
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Oncodesign Biotechnology
- Class
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia